Breaking News

Paratek Pharmaceuticals and Zai Lab Team Up

Form collaboration, development and license agreement for omadacycline in China

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Paratek Pharmaceuticals, a biopharmaceutical company focused on the development and commercialization of therapies based upon tetracycline chemistry, has entered into a collaboration with Zai Lab (Shanghai) Co., Ltd., a biopharmaceutical company based in China, to support the development and commercialization of omadacycline for patients in China. Paratek has granted to Zai Lab an exclusive license to develop, manufacture and commercialize omadacycline for the greater China territory, specifi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters